» Articles » PMID: 38256942

Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Jan 23
PMID 38256942
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukins, a diverse family of cytokines produced by various cells, play crucial roles in immune responses, immunoregulation, and a wide range of physiological and pathological processes. In the context of megakaryopoiesis, thrombopoiesis, and platelet function, interleukins have emerged as key regulators, exerting significant influence on the development, maturation, and activity of megakaryocytes (MKs) and platelets. While the therapeutic potential of interleukins in platelet-related diseases has been recognized for decades, their clinical application has been hindered by limitations in basic research and challenges in drug development. Recent advancements in understanding the molecular mechanisms of interleukins and their interactions with MKs and platelets, coupled with breakthroughs in cytokine engineering, have revitalized the field of interleukin-based therapeutics. These breakthroughs have paved the way for the development of more effective and specific interleukin-based therapies for the treatment of platelet disorders. This review provides a comprehensive overview of the effects of interleukins on megakaryopoiesis, thrombopoiesis, and platelet function. It highlights the potential clinical applications of interleukins in regulating megakaryopoiesis and platelet function and discusses the latest bioengineering technologies that could improve the pharmacokinetic properties of interleukins. By synthesizing the current knowledge in this field, this review aims to provide valuable insights for future research into the clinical application of interleukins in platelet-related diseases.

Citing Articles

A modern overview of the process of platelet formation (thrombocytopoiesis) and its dependence on several factors.

Ivanovna Gabrilchak A, Anatolievna Gusyakova O, Aleksandrovich Antipov V, Alekseevna Medvedeva E, Leonidovna Tukshumskaya L Biochem Med (Zagreb). 2024; 34(3):030503.

PMID: 39435166 PMC: 11493462. DOI: 10.11613/BM.2024.030503.


MAIT Cells in the Bone Marrow of Patients with Aplastic Anemia.

Vu L, Espinoza J, Nguyen H, Mizuno S, Takami A Int J Mol Sci. 2024; 25(18).

PMID: 39337644 PMC: 11432160. DOI: 10.3390/ijms251810160.


Peripheral inflammatory response in people after acute ischaemic stroke and isolated spontaneous cervical artery dissection.

Bauer A, Boehme C, Mayer-Suess L, Rudzki D, Knoflach M, Kiechl S Sci Rep. 2024; 14(1):12063.

PMID: 38802464 PMC: 11130263. DOI: 10.1038/s41598-024-62557-3.

References
1.
Hangoc G, Yin T, Cooper S, Schendel P, Yang Y, Broxmeyer H . In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood. 1993; 81(4):965-72. View

2.
Rodriguez-Fraticelli A, Wolock S, Weinreb C, Panero R, Patel S, Jankovic M . Clonal analysis of lineage fate in native haematopoiesis. Nature. 2018; 553(7687):212-216. PMC: 5884107. DOI: 10.1038/nature25168. View

3.
Balduini C . Treatment of inherited thrombocytopenias. Haematologica. 2022; 107(6):1278-1292. PMC: 9152979. DOI: 10.3324/haematol.2022.280856. View

4.
Zhang J, Ruan Y, Shen Y, Tao Q, Wang H, Tao L . Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia. Cytometry B Clin Cytom. 2016; 94(3):400-404. DOI: 10.1002/cyto.b.21494. View

5.
Machlus K, Johnson K, Kulenthirarajan R, Forward J, Tippy M, Soussou T . CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood. 2015; 127(7):921-6. PMC: 4760093. DOI: 10.1182/blood-2015-05-644583. View